Literature DB >> 16151820

Tumor cell dynamics and metastasis in advanced neuroblastoma.

Tatsuo Kuroda1, Toshiro Honna, Nobuyuki Morikawa, Yoshihiro Kitano, Yasushi Fuchimoto, Kan Terawaki, Masaaki Kumagai, Yukiko Tsunematsu, Hidekazu Masaki, Kentaro Matsuoka, Morihiro Saeki.   

Abstract

This study deals with the advancement process of neuroblastoma through clinical observations and circulating tumor cell exploration. Clinical feature, tumor biology, and circulating tumor cell detected by the previously described polymerase chain reaction (PCR) method were analyzed in 31 patients with advanced neuroblastoma treated in our department since 1991 through 2004. Treatment was completed in 28 patients, of whom 17 are alive without the disease and 11 died. The primary lesion was not confirmed in 2 patients with disseminated metastasis, both of whom showed positive circulating tumor cell. Circulating tumor cell was positive in 6 of 9 examined at their first appearance at the hospital, all had stage 4 disease, and 4 of the 6 (66.7%) died of systemic spread of the disease. N-myc was amplified in 15 patients, of whom only 2 (13.3%) died of systemic metastasis. N-myc amplification did not correlate with positive circulating tumor cell. A certain population of neuroblastoma may provide circulating tumor cells from the early period of the disease to form metastatic lesions independently of the primary lesion, which must be regulated by factors other than N-myc. Circulating tumor cells may suggest higher risk for systemic dissemination and poor prognosis.

Entities:  

Mesh:

Year:  2005        PMID: 16151820     DOI: 10.1007/s00383-005-1503-9

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN: 0179-0358            Impact factor:   1.827


  19 in total

1.  Surgical treatment of neuroblastoma with micrometastasis.

Authors:  T Kuroda; M Saeki; M Nakano; S Mizutani; M Endo; H Akiyama
Journal:  J Pediatr Surg       Date:  2000-11       Impact factor: 2.545

2.  International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.

Authors:  H Shimada; S Umehara; Y Monobe; Y Hachitanda; A Nakagawa; S Goto; R B Gerbing; D O Stram; J N Lukens; K K Matthay
Journal:  Cancer       Date:  2001-11-01       Impact factor: 6.860

3.  Treatment results of advanced neuroblastoma with the first Japanese study group protocol. Study Group of Japan for Treatment of Advanced Neuroblastoma.

Authors:  M Kaneko; Y Tsuchida; J Uchino; T Takeda; M Iwafuchi; N Ohnuma; H Mugishima; J Yokoyama; H Nishihira; K Nakada; S Sasaki; T Sawada; K Kawa; N Nagahara; S Suita; S Sawaguchi
Journal:  J Pediatr Hematol Oncol       Date:  1999 May-Jun       Impact factor: 1.289

4.  Determination of imbalance between MMP-2 and TIMP-2 in human neuroblastoma by reverse-transcription polymerase chain reaction and its correlation with tumor progression.

Authors:  T Ara; T Kusafuka; M Inoue; S Kuroda; M Fukuzawa; A Okada
Journal:  J Pediatr Surg       Date:  2000-03       Impact factor: 2.545

5.  Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: a preclinical model.

Authors:  Rouslan Kotchetkov; Jaroslav Cinatl; Roman Blaheta; Jens-Uwe Vogel; Jana Karaskova; Jeremy Squire; Pablo Hernáiz Driever; Thomas Klingebiel; Jindrich Cinatl
Journal:  Int J Cancer       Date:  2003-03-10       Impact factor: 7.396

6.  Arginine deiminase and other antiangiogenic agents inhibit unfavorable neuroblastoma growth: potentiation by irradiation.

Authors:  Hong Gong; Christoph Pöttgen; Georg Stüben; Werner Havers; Martin Stuschke; Lothar Schweigerer
Journal:  Int J Cancer       Date:  2003-09-20       Impact factor: 7.396

Review 7.  Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

Authors:  G M Brodeur; J Pritchard; F Berthold; N L Carlsen; V Castel; R P Castelberry; B De Bernardi; A E Evans; M Favrot; F Hedborg
Journal:  J Clin Oncol       Date:  1993-08       Impact factor: 44.544

8.  CD44s expression correlated with the International Neuroblastoma Pathology Classification (Shimada system) for neuroblastic tumours.

Authors:  M J Julia Munchar; N A Sharifah; R Jamal; L M Looi
Journal:  Pathology       Date:  2003-04       Impact factor: 5.306

9.  Neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction (RT-PCR) for tyrosine hydroxylase mRNA.

Authors:  S A Burchill; F M Bradbury; B Smith; I J Lewis; P Selby
Journal:  Int J Cancer       Date:  1994-06-01       Impact factor: 7.396

10.  Childhood cancer.

Authors:  R W Miller; J L Young; B Novakovic
Journal:  Cancer       Date:  1995-01-01       Impact factor: 6.860

View more
  2 in total

Review 1.  Cellular kinetics of neuroblastoma and the role of surgery.

Authors:  Tatsuo Kuroda
Journal:  Pediatr Surg Int       Date:  2011-07-19       Impact factor: 1.827

Review 2.  Opportunities and challenges of circulating biomarkers in neuroblastoma.

Authors:  Ricky M Trigg; Jacqui A Shaw; Suzanne D Turner
Journal:  Open Biol       Date:  2019-05-31       Impact factor: 6.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.